Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The National Marrow Donor Program

D Stroncek1, G Bartsch, H A Perkins

  • 1American Red Cross Blood Services, St. Paul, MN.

Transfusion
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trend analysis and regional tumor incidence in Germany for testicular cancer between 2003 and 2014.

Andrology·2019
Same author

[Unexpected differential diagnosis of urachal cancer].

Der Urologe. Ausg. A·2018
Same author

[Urolithiasis 2016 : Reliable, effective and low radiation exposure].

Der Urologe. Ausg. A·2016
Same author

[Patient blood management: Current state of the literature].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2015
Same author

Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.

British journal of cancer·2014
Same author

[Cystectomy in the elderly patient].

Der Urologe. Ausg. A·2013
Same journal

Investigation of the preanalytical stability of blood donor samples.

Transfusion·2026
Same journal

The need for dried plasma-Still a national issue: Where are we and recommendations.

Transfusion·2026
Same journal

Spray dried plasma manufactured from apheresis and whole blood derived plasma.

Transfusion·2026
Same journal

Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

Transfusion·2026
Same journal

AABB survey on directed blood donation practices.

Transfusion·2026
Same journal

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
See all related articles

The National Marrow Donor Program successfully addresses the shortage of HLA-identical sibling donors by facilitating unrelated-donor marrow transplants. This program significantly increases patient access to life-saving bone marrow donations.

Area of Science:

  • Hematology
  • Immunogenetics
  • Transplantation Medicine

Background:

  • The increasing success of marrow transplantation is hampered by the scarcity of HLA-identical sibling donors for a majority of patients.
  • Pilot studies demonstrated the feasibility of successful marrow transplantation between phenotypically HLA-identical, unrelated individuals.

Purpose of the Study:

  • To establish the National Marrow Donor Program (NMDP) to create a large registry of volunteer marrow donors.
  • To coordinate the complex processes of donor searches and donor-recipient matching for patients requiring bone marrow transplants.

Main Methods:

  • Development of a national registry of volunteer potential marrow donors, with HLA-A and -B antigen typing.
  • Initiation of donor searches for patients and facilitation of the matching process.

Related Experiment Videos

  • Establishment of a national network of donor and transplant centers for coordination and operation.

    • Main Results:

    • By November 1991, the NMDP registry included 457,205 potential donors.
    • Donor searches were initiated for 8,481 patients, with 99.8% finding at least one potential donor matched for three of four HLA-A and -B antigens.
    • Of 3,156 completed searches, 940 (29.8%) resulted in a transplant, with chronic myelogenous leukemia being the most common diagnosis (42.0%).

    Conclusions:

    • The NMDP effectively facilitates unrelated-donor marrow transplants, expanding donor availability for patients.
    • The program's infrastructure supports the ongoing identification of suitable donors and contributes to understanding the role of unrelated-donor transplants in treating various diseases.